biostudies-literatureSanmamed MFNational Cancer InstituteNCI NIH HHSNational Institutes of Health1988-1995https://www.ebi.ac.uk/biostudies/studies/S-EPMC5834104biostudies-literatureUnknown28(8)<h4>Background</h4>Surrogate biomarkers of efficacy are needed for anti-PD1/PD-L1 therapy, given the existence of delayed responses and pseudo-progressions. We evaluated changes in serum IL-8 levels as a biomarker of response to anti-PD-1 blockade in melanoma and non-small-cell lung cancer (NSCLC) patients.<h4>Patients and methods</h4>Metastatic melanoma and NSCLC patients treated with nivolumab or pembrolizumab alone or nivolumab plus ipilimumab were studied. Serum was collected at baseline; at 2-4 weeks after the first dose; and at the time-points of response evaluation. Serum IL-8 levels were determined by sandwich ELISA. Changes in serum IL-8 levels were compared with the Wilcoxon test and their strength of association with response was assessed with the Mann-Whitney test. Accuracy of Annals of oncology : official journal of the European Society for Medical OncologyChanges in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients.PMC5834104P50 CA121974SAF2011-22831SAF2014-52361-RMorgado MChen LSznol MMelero IPerez-Gracia JLAndueza MPWang JAlfaro CMartin-Algarra SBacchiocchi ASchalper KAKluger HRodriguez-Ruiz MEFusco JPOnate CHalaban RSanmamed MFPerez GGonzalez AGurpide AfalseChanges in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients.<h4>Background</h4>Surrogate biomarkers of efficacy are needed for anti-PD1/PD-L1 therapy, given the existence of delayed responses and pseudo-progressions. We evaluated changes in serum IL-8 levels as a biomarker of response to anti-PD-1 blockade in melanoma and non-small-cell lung cancer (NSCLC) patients.<h4>Patients and methods</h4>Metastatic melanoma and NSCLC patients treated with nivolumab or pembrolizumab alone or nivolumab plus ipilimumab were studied. Serum was collected at baseline; at 2-4 weeks after the first dose; and at the time-points of response evaluation. Serum IL-8 levels were determined by sandwich ELISA. Changes in serum IL-8 levels were compared with the Wilcoxon test and their strength of association with response was assessed with the Mann-Whitney test. Accuracy of 2017-01-01T00:00:00Z2017 Aug2025-04-19T15:18:08.534Z2019-03-26T23:48:52ZS-EPMC58341042859533610.1093/annonc/mdx190